யோகோகாமா நகரம் பல்கலைக்கழகம் மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from யோகோகாமா நகரம் பல்கலைக்கழகம் மருத்துவ மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In யோகோகாமா நகரம் பல்கலைக்கழகம் மருத்துவ மையம் Today - Breaking & Trending Today

Prognostic Marker Identified for Invasive Bladder Cancer

Prognostic Marker Identified for Invasive Bladder Cancer
by Angela Mohan on
June 1, 2021 at 12:56 PM
In the new study 32 patients developed recurrent disease and 15 patients showed progression.
A multivariate analysis revealed that non-BCG treatment was an independent risk factor for recurrence, and a higher De Ritis ratio was an independent risk factor for cancer progression.
Dr. Takashi Kawahara from The Yokohama City University Medical Center said, Bladder cancer is the eleventh most common malignant disease in the world, and non-muscle invasive bladder cancer (NMIBC) accounts for 75% of all bladder cancer cases.
The serum aspartate aminotransaminase /alanine aminotransaminase ratio was first reported by De Ritis in 1957, since then this ratio has been called the De Ritis ratio. ....

Takashi Kawahara , Childrenenuresis Bedwettingcancer Factscancertattoos , Yokohama City University Medical Center , Oncotarget Research Output , Health Benefits Of Dandelion Plant , Kawahara Research Team , High De Ritis , Lifestyle Habits , Homeopathyvesico Ureteric Reflux Causing , Bedwettingcancer Factscancertattoos , Cause Diseaseshealth Benefits , Bladder Cancer , Prognostic Marker , E Ritis Ratio , யோகோகாமா நகரம் பல்கலைக்கழகம் மருத்துவ மையம் , ஆரோக்கியம் நன்மைகள் ஆஃப் டேன்டேலியன் ஆலை , வாழ்க்கை பழக்கம் , சிறுநீர்ப்பை புற்றுநோய் ,

Oncotarget: Progression in high-risk non-muscle invasive bladder cancer

This Oncotarget study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC ....

Takashi Kawahara , Oncotarget Research Output , Impact Journals , Yokohama City University Medical Center , Kawahara Research Team , Medicine Health , ஒலி கிளவுட் , தாக்கம் பத்திரிகைகள் , யோகோகாமா நகரம் பல்கலைக்கழகம் மருத்துவ மையம் , மருந்து ஆரோக்கியம் ,

Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan

Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan
Font : A-A+
from Treatment with Lynparza
More Than 20,000 Patients in Japan Now Qualify for Genetic Testing
SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) In an announcement that will help more people with advanced prostate and pancreatic cancers in Japan, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will receive reimbursement for its BRACAnalysis
® Diagnostic System, which helps physicians determine whether certain patients will qualify and potentially benefit from treatment with the PARP inhibitor, Lynparza (olaparib). BRACAnalysis was approved by Japans Ministry of Health, Labour and Welfare (MHLW) in October 2020 as a companion diagnostic for these indications and the reimbursement decision is now in effect. ....

United States , Hideki Ueno , Jared Maxwell , Bracanalysis Cdx , Scott Gleason , Nicole Lambert , Hiroji Uemura , Hu Group Holdings Inc , Tsrl Inc , Bank Intl , Merck Co Inc , Yokohama City University Medical Center , International Agency For Research On Cancer , Japan Ministry Of Health , National Cancer Center Hospital , World Health Organization , Department Of Hepatobiliary , Prometheus Labs Inc , Genetics Inc , Exchange Commission , Supreme Court , World Cancer Research Fund , Department Of Urology , Alice Corp , Pancreatic Cancer , Japan Now Qualify ,